Harry Bleiberg
- Oncology top 0.1%
- Colorectal Cancer Treatments and Studies 68
- Cancer Treatment and Pharmacology 28
- Colorectal Cancer Surgical Treatments 13
- Hepatology top 0.5%
- Hepatocellular Carcinoma Treatment and Prognosis 23
- Pulmonary and Respiratory Medicine top 0.2%
- Gastric Cancer Management and Outcomes 47
- Gastroenterology top 1%
- Pathology and Forensic Medicine top 0.5%
- Genetic factors in colorectal cancer 24
-
- Nausea and vomiting management 19
- Cholangiocarcinoma and Gallbladder Cancer Studies 12
Harry Bleiberg
160 papers receiving 9.9k citations
Hit Papers
Peers
Comparison fields: 5 of 132
- Oncology 7.2k
- Hepatology 1.7k
- Pulmonary and Respiratory Medicine 4.2k
- Gastroenterology 464
- Pathology and Forensic Medicine 1.4k
Countries citing papers authored by Harry Bleiberg
This map shows the geographic impact of Harry Bleiberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Harry Bleiberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Harry Bleiberg more than expected).
Fields of papers citing papers by Harry Bleiberg
This network shows the impact of papers produced by Harry Bleiberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Harry Bleiberg. The network helps show where Harry Bleiberg may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Harry Bleiberg, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2015 | 172 | |
| 2 | Trends in colorectal cancer mortality and screening activities in European countries | 2013 | 2 |
| 3 | 2007 | 79 | |
| 4 | 2006 | 8 | |
| 5 | 2004 | 2 | |
| 6 | 2002 | 17 | |
| 7 | 2001 | 4 | |
| 8 | A clinical pharmacodynamic (Pd) and pharmacokinetic (Pk) phase I study of I.V. R101933, an inhibitor of MDR1 P-glycoprotein (PgP) given alone and in combination with Taxol in patients with solid tumors | 1999 | 1 |
| 9 | 1999 | 45 | |
| 10 | Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancerbreakdown → | 1998 | 786 |
| 11 | 1998 | 6 | |
| 12 | 1997 | 16 | |
| 13 | 1996 | 2 | |
| 14 | 1994 | 4 | |
| 15 | A phase I clinical trial of recombinant human interleukine-6 (rhIL-6) in solid tumors | 1992 | 1 |
| 16 | 1992 | 17 | |
| 17 | 1992 | 6 | |
| 18 | Étude en phase i de l'alizapride chez des patients cancéreux traites au cisplatine | 1983 | 4 |
| 19 | [Contribution of computerized axial tomography in hepatic tumor pathology. 1st experiences]. | 1977 | 1 |
| 20 | [Autoradiographic measurement of cell proliferation at different levels of the normal and pathologic gastrointestinal tract. Use of biopsies incubated in vitro]. | 1971 | 2 |
About Harry Bleiberg
Harry Bleiberg is a scholar working on Oncology, Hepatology, Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine and Surgery, having authored 163 papers that have together received 10.2k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (68 papers), Gastric Cancer Management and Outcomes (47 papers), Cancer Treatment and Pharmacology (28 papers), Genetic factors in colorectal cancer (24 papers), Hepatocellular Carcinoma Treatment and Prognosis (23 papers), Nausea and vomiting management (19 papers), Colorectal Cancer Surgical Treatments (13 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (12 papers). The work is most often cited by research in Oncology (7.2k citations), Hepatology (1.7k citations), Pulmonary and Respiratory Medicine (4.2k citations), Gastroenterology (464 citations) and Pathology and Forensic Medicine (1.4k citations). Harry Bleiberg has collaborated with scholars based in Belgium, France and Netherlands. Frequent co-authors include Eric Van Cutsem, David Cunningham, Yves Humblet, David Khayat, Salvatore Siena, M. Mueser, A. Harstrick, Armando Santoro, Chris Verslype and Ian Chau. Their work appears in journals such as European Journal of Cancer, Journal of Clinical Oncology, Annals of Oncology, Anti-Cancer Drugs and British Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.